Skip to content
Sign in
SWC 2026 FinalistGrand Final: Lunch Block

3D Armour

Costa Rican MedTech replacing plaster casts with custom, water-resistant 3D-scanned and 3D-printed orthopedic splints.

San José, Costa Rica, Latin AmericaMedTech & devices, Custom 3D-printed orthopedic splints
Stage
UndeterminedNo documented AI
Product
On the marketNone known
Funding raised
Undisclosedno funding
Founded
20242 years ago
Founders
—
Global score
3.0Grade DRank 126 of 151

Overview

Costa Rican medical technology startup that makes custom, water-resistant orthopedic splints using 3D scanning and printing, as an alternative to traditional casts; incubated at the Clínica Bíblica Life Science Center for Innovation (San José). Founders not confirmed.

Traction

None known

Site with a catalog and online store of 3D-printed splints, but no customers, volumes or clinical partners quantified (Clínica Bíblica incubation).

Market

Orthopedic splints

Fracture and sprain immobilisation is a high-volume, low-margin market dominated by plaster and fibreglass casts bought by hospitals, orthopaedic clinics and emergency departments. Custom 3D-printed splints promise comfort, hygiene (water resistance, ventilation) and fewer skin complications, and become viable as scanners and printers get cheaper. Adoption depends on clinician workflow (scan-to-fit time), cost per splint versus a cast, and reimbursement or private-pay acceptance. Latin American private hospitals are a credible first market.

Addressable market

2025
$1.7B
2030
$2.7B
+9.6% a year

Orthopedic splints: $1.69bn in 2025, $2.67bn in 2030 (CAGR 9.6%, Mordor Intelligence).

Customers

Private hospitals, orthopaedic and sports-medicine clinics, patients paying out of pocket

Who signs the cheque

Orthopaedic surgeons and clinic/hospital procurement; patients for premium options

Geographies

  • Costa Rica
  • Central America

Drivers

  • Patient demand for comfort and water resistance
  • Falling cost of 3D scanning and printing
  • Sports-medicine and premium private care

Headwinds

  • Cost and turnaround versus traditional casts
  • Clinical evidence and reimbursement
  • Small local market

Global orthopedic splint market of $1.69bn in 2025, $2.67bn in 2030 (CAGR 9.6%) according to Mordor Intelligence.

Scalability 4/10. Custom physical manufacturing (scan + 3D printing) and country-by-country medical approval limit replication.

Market source: marketresearch.com

Technology

Category

Personalised medical device (additive manufacturing)

No documented AI

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

in market

How it works

The patient's limb is 3D-scanned and a personalised splint is 3D-printed, lighter and better ventilated than a cast. No AI is used.

Moat

Weak: the scan-to-print workflow is widely replicable; defensibility would come from clinical partnerships, speed and materials.

Differentiation

Water-resistant, ventilated, custom fit versus plaster/fibreglass casts.

Integration points

  • Hospital orthopaedic workflows
  • Sports clubs and physiotherapy
  • Padding / liner material suppliers

Depends on

  • 3D scanners and printers
  • Medical-grade materials
  • Clinical acceptance and regulatory registration

Use of AI

No use of AI mentioned

Product in detail

3D scan of the limb and 3D printing of personalized splints, lighter and better ventilated than a cast.

Business

Model
Sale of custom splints through an online store and clinics.
Revenue logic
Per-splint price (not published).
Go-to-market
Clinical incubation at Clínica Bíblica's Life Science Center plus online catalogue.

Next milestones

  1. Named hospital partner with volumes
  2. Clinical outcome data versus casts
  3. Regional expansion beyond Costa Rica

Key risks

  • No quantified traction
  • Local market only
  • Competition from low-cost casts

Opportunities

3 found in the network

Concrete moves for 3D Armour inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Co-development 2
  • Investors 1

Co-development2

An integration or joint product

Co-develop custom PFAS-free foam liners for printed splints

Printed splints need a comfortable, water-tolerant liner; Super Foam casts PFAS-free shock-absorbing foam to custom shapes with samples in two days. A liner co-designed from the same scan file would improve comfort and give Super Foam a medical application.

30%confidence

Evidence from the records

  • “custom, water-resistant orthopedic splints using 3D scanning and printing”
  • “Patented PFAS-free foam cast on demand (adjustable formulation, density, shape), samples in 2 days”
If it works
A liner prototype tested on the next splint batch.
First step
Send Super Foam two splint scan files and request liner samples.

Produce custom-fit shells for smart shin guards

Cresento's sensor shin guards must fit each player; 3D Armour's scan-and-print pipeline can produce custom shells, and sports injuries are also a splint market. Cresento gets a premium fit option; 3D Armour gets a sports channel.

20%confidence

Evidence from the records

  • “3D scan of the limb and 3D printing of personalized splints”
  • “AI-enabled smart shin guards that measure footballers' intensity, fatigue, speed and movement”
If it works
A custom-shell prototype for Cresento's pre-order customers.
First step
Propose a remote scan-to-print test on two Cresento test players.

Investors1

A fund whose thesis fits

Apply to Start-Up Chile’s pre-seed programme

Start-Up Chile funds pre-seed founders from Latin America and beyond and backed network MedTech Medetechni, which can share its application experience. It would fund regional expansion from Costa Rica to the Southern Cone.

25%confidence

Evidence from the records

  • “Start-Up Chile (CORFO), BioLeap, OpenSeniors”
  • “Not investable as it stands.”
If it works
Non-dilutive pre-seed capital and a Chilean beachhead.
First step
Ask Medetechni's founders about their Start-Up Chile application and timing.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

San Salvador VC whose $11M IDB Lab-backed fund backs ~25 early-stage startups in El Salvador, Honduras and Guatemala, ≥25% women-led.

Costa Rican 3D-printed orthopaedic splints — Central America health, outside target countries.

25%confidence

Evidence from the records

  • “"HealthTech"”
  • “Custom 3D-printed orthopedic splints”
  • “Site with a catalog and online store of 3D-printed splints, but no customers, volumes or clinical partners quantified (Clínica Bíblica incubation).”
Intro path
Founder-to-founder intro via Pulster.ai (network portfolio company of Innogen Capital Ventures).
First step
Low priority.

Investment analysis

3.0D

Grade D

Rank 126 of 151

Disruption4.0/10
Business model2.0/10
Market3.0/10
Risk(lower is better)8.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

Not investable as it stands.

Disruption

4/10

3D-printed orthopedic splints: an already widespread concept.

Business model

2/10

Online store with no customers or volumes.

Market

3/10

TAM orthopedic splints ~$1.69bn (base 4), low scalability 4/10 (−1), no proven international expansion (0) → 3/10.

Risk

8/10

Lower is better

High risk: no data, medical regulation.

Strengths

  • Concrete product
  • Clinical incubation

Risks

  • No traction
  • Local market

Funding

Undisclosed, no funding
  1. non précisée

    incubation (Life Science Center for Innovation, Clínica Bíblica, Costa Rica)not disclosed

    Clínica Bíblica LSCI

  2. 5 mars (année non précisée)

    awardnot disclosed

    INCAE Entrepreneur Award, 9th edition (top 3, Pitch category winner)

Amount used in the study. No funding round; incubation and award amounts not disclosed.

Note. no public funding round found

Costa Rican identity confirmed by El Financiero (water-resistant 3D-printed splints, INCAE Entrepreneur Award). Founders still not found; the SWC Costa Rica 2025 regional was won by Bee Loyal Card, SWC 2026 qualification not confirmed.

Team

No founders listed yet.

Sources

Identification confidence
medium
Founding year: 2024 (high confidence)
Official site: founded by biomedical engineer Stephan Peters “a inicios de 2024” 3darmour.com
  1. 13darmour.com/
  2. 2elfinancierocr.com/etiqueta/3darmour/
  3. 3elfinancierocr.com/emprender/ranking-regional-destaca-a-seis-startups/WWA2AHQJ

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet